Victor Davis Hanson explains why Secretary of War Pete Hegseth should be thanked rather than face impeachment.

A number of diseases tend to peak in the winter, thanks to indoor gatherings that help germs spread. The list includes not ...

María Corina Machado reappeared on the global stage as the Trump administration ramped up its pressure campaign against ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Moderna's chief technical ...

An older resident of Washington state has died after contracting the H5N5 strain of avian influenza, according to state health officials. The patient lived in Grays Harbor County and was receiving ...

Moderna told investors that it still thinks it can stop losing money in 2028, and that its financial outlook remains strong, but that it had taken out a $1.5 billion loan to shore up its balance sheet ...

Moderna is pruning three investigational vaccines from its pipeline, while also securing additional funding, giving the company more financial flexibility as it strives to hit 10% revenue growth in ...

Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases. The ...

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match the sales highs it experienced during the pandemic. Now, in an effort to ...

Shares of Moderna, Inc. (NASDAQ: MRNA) are falling Thursday. The Massachusetts-based biotech company made two significant announcements regarding its finances and business strategy. What To Know: ...

Ahead of its Analyst Day event on Thursday, Moderna (MRNA) indicated ~10% revenue growth for next year and increased its outlook for year-end liquidity, following up to a $1.5B loan from Ares ...

(Reuters) -Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management, as it targets up to 10% revenue growth next year. The vaccine maker, which is expected to unveil ...